Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 50Lymphoma, Non-Hodgkin 45Lymphoma 34Lymphoma, Mantle-Cell 30Lymphoma, Follicular 26Multiple Myeloma 23Hodgkin Disease 21Lymphoma, Large B-Cell, Diffuse 18Recurrence 13Lymphoma, B-Cell, Marginal Zone 12Leukemia 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Neoplasms 6Lymphoma, T-Cell 5Waldenstrom Macroglobulinemia 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, B-Cell 4Leukemia, Myeloid, Acute 4Leukemia, B-Cell 4Breast Neoplasms 4Small Cell Lung Carcinoma 3Sezary Syndrome 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms, Plasma Cell 3Myelodysplastic Syndromes 3Mycosis Fungoides 3Lymphoma, T-Cell, Peripheral 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Extranodal NK-T-Cell 3Immunoblastic Lymphadenopathy 3

Interventions

rasburicase 8Urate Oxidase 4Allopurinol 3venetoclax 1obinutuzumab 1alvocidib 1Uric Acid 1Pegloticase 1Oxidoreductases 1Lenalidomide 1Febuxostat 1Carbamates 1Bendamustine Hydrochloride 1Amides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Tumor Lysis Syndrome × Bendamustine Hydrochloride × Clear all
NCT03406156 2024-08-06

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

AbbVie

Phase 3 Completed
120 enrolled 14 charts
LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Neoplasms, Tumor Lysis Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡